In a report released today, Michael Matson from Needham maintained a Buy rating on Merit Medical Systems (MMSI), with a price target of $73. The company’s shares opened today at $62.18.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.0% and a 65.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Merit Medical Systems has an analyst consensus of Strong Buy, with a price target consensus of $72.33.
See today’s analyst top recommended stocks >>
Based on Merit Medical Systems’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $9.19 million. In comparison, last year the company had a net profit of $5.27 million.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.
